Regulatory fee revision for health products

The Health Sciences Authority (HSA) regulates health products to ensure that they meet the required standards of quality, safety and efficacy. There are fees in place to help cover the cost of registration, licensing, notification and permit issuance for therapeutic products, medical devices, Chinese proprietary medicines, cosmetic products, cell tissue and gene therapy, oral dental gums and retail pharmacies.

With effect from 1 July 2024, a fee increase averaging 5% will be implemented, with a minimum increase of $1 and capped at $200 per fee item. This fee revision is necessary to recover part of the costs for the services rendered to businesses.

The revised fees are listed below:

• Medical Devices
• Therapeutic Products
• Controlled Drugs and Psychotropic Substances
• Form A Poisons Licence
• Cell, Tissue or Gene Therapy Products (CTGTP)
• Chinese Proprietary Medicines
• Cosmetic Products
• Retail Pharmacy Licence
• Medical Advertisements & Sales Promotion 

This fee revision is necessary to recover part of the costs for the services rendered to businesses.

HSA will continue to streamline our processes and deliver value to all our stakeholders. Read about our initiatives here (NEX2US Newsletter and Regulatory updates).

For enquiries on the fee revision, please email us at: contact_hprg@hsa.gov.sg

Subscribeto stay up to date with HSA news and regulatory updates.

Regulatory Updates